[膀胱癌术后膀胱内灌注治疗的预防复发效果]
[The preventive recurrent results of postoperative intravesical instillation therapy in bladder cancer].
作者信息
Zhang S, Li H, Cheng H
机构信息
Department of Urology, First Affiliated Hospital, West China University of Medical Sciences, Chengdu.
出版信息
Zhonghua Wai Ke Za Zhi. 1995 May;33(5):304-6.
From Jan. 1988 to Nov. 1992, 441 patients with bladder carcinoma were hospitalized in our department. 385 of them were treated by transurethral resection of bladder tumor (TURBT) or partial cystectomy. After surgical management, the instillation therapy with BCG, TTP or MMC, etc was used to prevent tumor recurrence in 321 patients. Follow-up for 1-7 years showed that the mortality rate was 6.9% (22/318), and the tumor recurrence rate in BCG, TTP, MMC and control groups was 18.1%, 31.2%, 29.6% and 46.1% respectively. The factors influencing the tumor recurrence and the prophylactic effect of BCG instillation immunotherapy were discussed.
1988年1月至1992年11月，我科收治膀胱癌患者441例。其中385例行经尿道膀胱肿瘤切除术（TURBT）或膀胱部分切除术。手术治疗后，321例患者采用卡介苗（BCG）、噻替派（TTP）或丝裂霉素（MMC）等膀胱灌注治疗预防肿瘤复发。随访1至7年，结果显示死亡率为6.9%（22/318），卡介苗、噻替派、丝裂霉素及对照组的肿瘤复发率分别为18.1%、31.2%、29.6%和46.1%。本文对影响肿瘤复发的因素及卡介苗膀胱灌注免疫治疗的预防效果进行了讨论。
Zotero 插件